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was the key element to efficiently compete and deregulate FH and FH-me-
diated convertase decay locally on tumour cell surface. FHR4 can thus rep-
resent a novel therapeutic molecule, when expressed as a multimeric entity
and associated with an anchoring system, to locally shift the complement
steady-state towards activation on tumour cell surface.
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1. Introduction
The complement system is a major humoral arm of
innate immunity (Morgan and Kavanagh, 2018; Reis
et al., 2019), acting as a fast and efficient immune
surveillance system that can discriminate among
healthy host tissues, cellular debris, apoptotic cells and
foreign intruders. Complement can be rapidly acti-
vated against invading pathogens, either directly
through activation of the complement alternative path-
way (AP) or indirectly through the activation of the
complement classical pathway (CP) or complement lec-
tin pathway (LP). Sequential events of the comple-
ment-directed inflammatory cascades lead to the
generation of C3 and C5 convertases that orchestrate
the assembly of membrane attack complex (MAC)
C5b-9, leading to direct complement-dependent cyto-
toxicity (CDC) and subsequent cell killing (Bubeck,
2014). Moreover, C3b degradation products on opso-
nised targets promote the activation of phagocytic
effector cells and of cytotoxic cells, such as natural
killer (NK) cells, via CR1 (CD35), CR3 (CD11b/
CD18) and CR4 (CD11c/CD18) receptors, leading to
complement-dependent cell-mediated phagocytosis
(CDCP) and complement-dependent cell-mediated
cytotoxicity (CDCC) (Gelderman et al., 2004). Direct-
ing the selective complement activation towards
unwanted cells to promote destructive cell targeting is
an attractive strategy (Carter and Lieber, 2014), acti-
vating AP within few minutes and further promoting
CDC and/or CDCC and (Gelderman et al., 2004).
The first approach to modulate complement was
established with the development of monoclonal anti-
bodies (mAbs), promoting antibody-dependent cell-
mediated cytotoxicity (ADCC) and CDC for many
types of tumours (Meyer et al., 2014). Although the
therapeutic potential for a large majority of antibodies
is mainly based on ADCC, contribution of CDC
remains controversial (Derer et al., 2014). Four known
therapeutic mAbs (i.e., alemtuzumab, cetuximab, ofa-
tumumab and rituximab) induce efficient CDC and
opsonisation on B-cell lymphomas in chronic lympho-
cytic leukaemia (CLL) (Diebolder et al., 2014; Gancz
and Fishelson, 2009; Gorter and Meri, 1999; Idusogie
et al., 2001; Richards et al., 2008; Zent, 2008; Zent
et al., 2016). The efficiency of mAb-mediated CDC to
kill tumour cells in vivo is less clear with solid
tumours. Overexpression of membrane complement
regulatory proteins (mCRPs) such as membrane cofac-
tor protein (CD46), decay accelerating factor (CD55)
and protectin (CD59) is considered to be one of the
critical mechanisms by which solid tumours can resist
CDC (Gancz and Fishelson, 2009; Golay et al., 2001;
Golay et al., 2000). Substantial amounts of research
have focused on engineering Fc variant antibodies to
improve the capacity of antibodies to promote CDC
and/or ADCC or ADCP (Diebolder et al., 2014; Idu-
sogie et al., 2001; Richards et al., 2008). The clinical
efficacy of such engineered antibodies remains to be
determined in clinical trials.
Several approaches aiming at focusing C3b deposi-
tion on targets to mediate CDC have been proposed
(Elvington et al., 2012; Kontermann et al., 1997;
Shaughnessy et al., 2014). Factor H (FH) is the main
regulator of the initial activation of the AP, which is
essential in restricting the action of complement to
activating surfaces (Ferreira et al., 2010; Kopp et al.,
2012). FH maintains the density of C3b molecules on
host surfaces below a critical threshold to control C3b
amplification and prevent the occurrence of comple-
ment-mediated tissue damage (Jozsi et al., 2015). FH-
related protein 4 (FHR4) was recently described as a
positive regulator of the complement AP (Hebecker
and Jozsi, 2012). FHR4, like FHR3, recruits C3b to a
cell surface by competing with FH, thus promoting
immune activation by acting as an antagonist of FH
(Caesar et al., 2014; Hebecker and Jozsi, 2012). FHR4
shares sequence homologies with FH short consensus
repeat (SCR) domains 6, 8, 9, 19 and 20, which dis-
play two C3b binding sites, but is unable to inactivate
C3b because of the lack of the FH C3b-regulatory
domains (Jozsi et al., 2015). Importantly, FHR4-
bound C3b favours the subsequent binding of factor B
(FB) and properdin to generate FHR4-C3bBb conver-
tases that are resistant to FH–mediated decay
(Hebecker and Jozsi, 2012). Therefore, FHR4 acts as
an enhancer of opsonisation and facilitates the recog-
nition of dying cells (Hebecker and Jozsi, 2012; Mihlan
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et al., 2009) or pathogens by the host’s immune
surveillance system for further elimination by direct
cell killing or by phagocytosis.
We hypothesised that a multimeric recombinant
FHR4 molecule, combined to a targeting moiety
recognising a tumour-associated antigen, could selec-
tively accumulate on target tumour cells, enhancing
the local stoichiometry of FHR4, thereby allowing the
tumour cell-established complement inhibition thresh-
old (CIT) to be overcome. We used the C4b-binding
protein (C4bp) C-terminal of the a and b chains as a
scaffold for multimerisation (Dervillez et al., 2006;
Oudin et al., 2000) to generate trifunctional heteromul-
timers harbouring (a) multivalent FHR4; (b) multiva-
lent VHH against HER2; and (c) a monovalent
enhanced GFP (eGFP) tracking function (TrF). In the
present work, we investigated the mode of action of
the immunoconjugates in vitro against HER2-tumour
cells. We showed that optimised immunoconjugates
expressing high FHR4 valences were the most potent
immunoconjugates to activate AP and subsequently
induce massive C3b deposition, MAC binding and
CDC of SK-OV-3, BT474 and SK-BR3 HER2-overex-
pressing tumour cell lines, as well as complement-me-
diated phagocytosis.
2. Materials and methods
2.1. Cells and antibodies
All multimers were generated from stable transfected
HEK293 cells (ATCC CRL-1573, Manassas, VA,
USA) cultured with Dulbecco’s modified Eagle’s med-
ium (Westburg, Leusden, the Netherlands) supple-
mented with 10% heat-inactivated FBS (Life
Technologies Europe BV, Merelbeke, Belgium),
1 UmL1 of penicillin, 1 lgmL1 of streptomycin
(Wesburg) and 4 mM of glutamine (Westburg). BT474
(HTB-20), SK-OV-3 (HTB-77) and SK-BR-3 (HTB-
30) cells were kindly provided by M. Kirschfink
(University of Heidelberg). Rabbit anti-6-His and goat
anti- enterokinase cleavage site (DDDDK) polyclonal
antibodies (pAbs) were purchased from Bethyl (ImTec
Diagnostic NV, Antwerpen, Belgium). A mouse anti-
human FHR4 mAb was purchased from R&D Sys-
tems Europe Ltd (Bio-Techne, Abingdon, UK). Mouse
anti-human C3b/iC3b (Clone 7C12) mAb, unconju-
gated or phycoerythrin (PE) conjugated, was pur-
chased from CEDARLANE (Sanbio B.V., Uden, the
Netherlands). The mouse anti-human C4d monoclonal
antibody, the FB-depleted, C1q-depleted and C5-de-
pleted human sera [FB-deficient human serum
(∆FBHS), C1q-deficient human serum (∆C1qHS) and
C5-depleted human serum (∆C5HS), respectively] were
purchased from Quidel (TECOmedical Benelux BV,
Utrecht, the Netherlands). The following antibodies
were purchased from ABCAM (Cambridge, UK):
mouse anti-human C5b-9 (Clone aE11) mAb and
AF647-conjugated donkey anti-goat immunoglobulin
G (IgG) pAb. AF647-conjugated goat anti-rabbit IgG
pAb was purchased from Invitrogen (Thermo Fisher
Scientific BVBA, Merelbeke, Belgium). PE-conjugated
donkey anti-rabbit IgG pAb was provided by eBio-
science (Affymetrix, Rennes, France). Allophycocyanin
(APC)-conjugated goat anti-mouse IgG was purchased
from Jackson ImmunoResearch (Sanbio). PKH26 red
fluorescent cell linker was provided by Sigma-Aldrich
(Overijse, Belgium). Propidium iodide (PI), carboxyflu-
orescein succinimidyl ester (CFSE) cell tracer, 40,6-di-
amidino-2-phenylindole dihydrochloride (DAPI) were
from Life Technologies (Europe BV). Purified C3b
and FH were purchased from Merck KGaA (Darm-
stadt, Germany). Trastuzumab (Herceptin) and per-
tuzumab (Perjeta) therapeutic antibodies were
obtained from Roche (Prophac, Howald, Luxem-
bourg). The PE- or APC-conjugated mouse anti-hu-
man IgG was from BD Pharmingen (Becton
Dickinson Benelux NV, Erembodegem, Belgium). The
rabbit anti-mouse IgG horseradish peroxidase (HRP)
and goat anti-rabbit IgG HRP-conjugated antibodies
were from Sigma-Aldrich. Mouse anti-human CD46
AF647-conjugated IgG1 (Clone MEM-258) and mouse
anti-human CD55 R-phycoerythrin (RPE)-conjugated
IgG1 (Clone 67) were from Bio-Rad (Bio-Rad Labora-
tories NV, Temse, Belgium). The mouse anti-human
CD59 fluorescein isothiocyanate (FITC)-conjugated
IgG2a (Clone MEM-43) was from ImmunoTools
GmbH (Friesoythe, Germany). The goat anti-mouse
IgG AF546-conjugated secondary antibody was from
Thermo Fisher Scientific BVBA. Human recombinant
macrophage colony-stimulating factor (M-CSF) was
from Enzo Life Sciences BVBA (Antwerpen, Belgium).
Sheep erythrocytes (50% blood suspension in Alsever
buffer) and rabbit haemolytic anti-sheep erythrocyte
serum (haemolysin) were purchased from Virion\Ser-
ion (Serion Immunologics, W€urtzburg, Germany).
2.2. Establishment of expression cassettes for
multifunctional heteromultimers
The backbone bi-cistronic pEF-IRESpac expression
vector was used to clone all expression cassettes between
EcoRI and XbaI restriction sites of its multiple cloning
sites (Hobbs et al., 1998). The signal peptide cloned
between EcoRI and Bgl2 is from the tumour necrosis
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factor receptor superfamily member 16 (UniProt no.
P08138) (Hildinger et al., 2001). cDNA encoding human
FHR4A (UniProt no. Q92496), modified 2D3 and 47D5
VHH anti-HER2 (2D3 VHH recognising trastuzumab-
competing epitope or 47D5 VHH recognising per-
tuzumab-competing epitope, adapted from patent
WO2008068280) and eGFP were synthesised (Pro-
teoGenix SAS, Schiltigheim, France) between the Bgl2
and BspE1 restrictions sites. cDNA encoding human
C4bp C-terminal a-chain (UniProt no. P04003, aa: 540–
597) and the third complement control protein (CCP3
or SCR3) plus the C-terminal end of the human C4bp
b-chains (UniProt no. P20851, aa: 137–252) were cloned
as previously described (Dervillez et al., 2006). FHR4
was spanned between Bgl2 and BspE1, (c-myc tag, a 59
(SGGGGS) spacer (5L), C4bpa and a His tag, and the
last four components were cloned between BspE1 and
XbaI. The 2D3 or 47D5 VHH anti-HER2 was cloned in
the same expression cassette with His tag to generate
bifunctional heteromultimers lacking FHR4 or with
FLAG tag to generate trifunctional heteromultimers.
eGFP TrF was spanned between Bgl2 and BspE1, a 19
(SGGGGS) spacer (1L) and SCR3.C4bpb, the last two
components cloned were between BspE1 and XbaI.
2.3. Production of multifunctional
heteromultimers
During Step 1, HEK293 cells were cotransfected by
using lipofectamine 2000 (Invitrogen, Thermo Fisher
Scientific BVBA) with TrF and targeting function (TaF)
expression vectors. The TaF vector contains either the
2D3 VHH anti-HER2 (recognising trastuzumab-com-
peting epitope) or the 47D5 VHH anti-HER2 (recognis-
ing pertuzumab-competing epitope) genes, as
summarised in Fig. S1. Stable transfection was estab-
lished using puromycin (InVivogen, Toulouse, France).
Bifunctional heteromultimer-containing crude super-
natants of single-isolated clones were tested on BT474
breast cells by flow cytometry using an anti-FLAG or
an anti-His antibody. Single clones expressing the high-
est amounts of bifunctional heteromultimers were
expanded. During Step 2 (Fig. S1), bifunctional hetero-
multimer-expressing selected clones were cotransfected
with AP-effector function (EFF) vectors containing
FHR4 and pTK-Hygro (Clontech Laboratories Inc.,
Takara Bio Europe, Saint-German-en-Laye, France).
Stable transfected cells were selected using both puro-
mycin and hygromycin (Carl Roth GmbH Co. KG,
Karlsruhe, Germany). Supernatants from single-isolated
clones were screened for the mean FHR4 expression on
BT474 target cells. Ratios of mean fluorescence intensity
(MFI) His of bifunctional heteromultimers with FLAG
and with His correspond, respectively, to lowest
(His = 0) and highest (His = 7) FHR4 valence to eGFP
MFI and allow to establish a calibration curve. His/
eGFP MFI ratios from each single-isolated clone were
further assigned to the calibration curve to determine
the mean FHR4 valence.
2.4. Multimer purification by using His-Trap
affinity chromatography
Multimer-expressing HEK293 cells were cultured in
FBS-free Opti-MEM medium (Life Technologies Eur-
ope BV). Supernatants were purified using BioLogic
DuoFlow 10 medium-pressure liquid chromatography
system (FPLC; Bio-Rad Laboratories NV) connected to
Nickel His-Trap 5 mL columns (GE Healthcare, VWR,
Leuven, Belgium). Elution was performed using 20 mM
phosphate buffer, pH 7.4 that contained 500 mM of
sodium chloride (NaCl) and 500 mM of imidazole
(Sigma-Aldrich). Purified multimers were concentrated
on Amicon Ultra 15, 50 K MWCO (Millipore-Merck
Chemicals NV/SA, Evere, Belgium), dialysed against
PBS using Slide-A-Lyzer dialysis cassettes with 20K
MWCO (Thermo Fisher Scientific) and quantified using
NanoDrop 1000 (Thermo Fisher Scientific). To further
enrich in high-FHR4 valence molecular species, trifunc-
tional FHR4-heteromultimers were purified using an
improved protocol including a first washing step of
50 mM imidazole followed by 125 mM imidazole to
partly eliminate the molecular species with low-FHR4
valence. A final two-step elution was then performed
using 1 M imidazole introducing a 2 h-stop/resume in-
between (Fig. S3). Collected fractions from steps with
1 M imidazole peak 1 and peak 2 were pooled as frac-
tions (f2) and 3 (f3), respectively. The fractions were
concentrated, dialysed and quantified as described
above in this section.
2.5. Multimer-mediated AP activation, MAC
binding and CDC
To assess multimer-directed C3b deposition on HER2-
expressing tumour cells, purified FHR4/VHH(T),
FHR4/VHH(P) multimers and control therapeutic anti-
bodies were incubated separately or in combinations at
saturating concentrations (15 µgmL1) with SK-OV-3,
BT474 or SK-BR3 tumour cells in gelatin veronal buffer
containing CaCl2 and MgCl2 (GVB
++) and 30% ABO-
compatible normal human serum (NHS) from a healthy
donor for 30 min at 37 °C. After washing with PBS/1%
decomplemented FBS, cells were then stained with a
mouse anti-human C3b mAb and a rabbit anti-His
pAb, followed by anti-mouse IgG/APC and anti-rabbit
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IgG/PE secondary antibodies for flow cytometry, or a
mouse anti-human C5b-9 antibody to measure the
MAC binding on cells. For multimer-mediated CDC,
15 µgmL1 of multimers (or antibodies) was incubated
with SK-OV-3, BT474 or SK-BR3 cells in GVB++ sup-
plemented with 30% ABO-compatible NHS for 30 min
at 37°C. Cells were incubated with a live/dead (L/D)
near IR and fixed with 1% paraformaldehyde (PFA) to
provide the percentage of dead cells. Percentage of dead
cells was expressed as number of dead cells (live/dead-
positive cells) divided by the total number of cells anal-
ysed. FH-mediated dose–response inhibition of on C3b
deposition induced by the optimised high-FHR4 valence
multimer was performed by incubating SK-OV3 cells
with constant concentrations of purified FHR4/VHH(T)
multimers (15 µgmL1) together with twofold serial
dilutions of commercial soluble FH (starting at
125 µgmL1) in GVB++ containing 30% ∆C5HS for
30 min at 37 °C.
To demonstrate that FHR4-heteromultimers activate
the AP, SK-OV3 cells (105 cells per condition) were
incubated for 30 min at 4 °C with saturating concen-
trations (30 µgmL1) of either FHR4/VHH
(T) + FHR4/VHH(P) multimers, trastuzumab + per-
tuzumab, the VHH(T) control multimer or no mole-
cules. After washing with PBS/1%FBS, cells were then
incubated with 30% NHS in (a) GVB++; or (b) gelatin
veronal buffer containing MgCl2 and EGTA (without
CaCl2; GVB
+); (c) 30% ∆C1qHS; (d) 30% ∆FBHS; (e)
30% ∆FBHS + 200 µgmL1 commercial FB; or (f)
with 30% ∆C5HS for 30 min at 37 °C. After one
washing with PBS/1%FBS, cells were stained with
either an anti-human C3b (7C12) or an anti-human
C4d mAb for 30 min at 4 °C, followed by a staining
with an anti-human IgG antibody PE-conjugated.
After washing, cells were fixed with PBS/1% PFA and
analysed using flow cytometry.
2.6. Confocal microscopy analysis
To visualise multimer-mediated AP activation and
MAC binding by confocal microscopy, BT474 cells
were incubated with 20 µgmL1 purified optimised
FHR4/VHH(T) multimers in GVB
++ supplemented
with 25% ABO-compatible NHS or heat-inactivated
NHS (HIS). The cells were stained with mouse anti-
human C3b/iC3b (7C12) or C5b-9 (aE11) mAb, fol-
lowed by an anti-mouse IgG AF546-conjugated sec-
ondary antibody. Cells were then fixed with 1% of
PFA. Images were captured at 40 or 60-time magni-
fications using a Zeiss LSM510 confocal microscope
(Zeiss International, Oberkochen, Germany). Images
were recorded at different focal planes; Z stacks
from ~ 22 stacked-up sections were generated by
incrementally stepping through the cell volume using
a focal drive. The Z sections were stacked using IM-
AGE J (NIH, Bethesda, MA, USA) to reconstruct
three-dimensional (3-D) images.
2.7. Surface plasmon resonance analysis
Surface plasmon resonance (SPR) experiments were
conducted using a Biacore 3000 system (GE Healthcare
Europe GmbH, Diegem, Belgium). CM5 sensor chips
were used with HBS-EP buffer (10 mM Hepes pH 7.4,
150 mM of NaCl, 3 mM of EDTA and 0.05% of surfac-
tant P20; GE Healthcare). Activation of surfaces and
ligand immobilisations were achieved with the primary
amine coupling kit according to the manufacturer’s
instructions. Ten thousand RU of each of the purified
high-FHR4 valence trifunctional heteromultimers
[FHR4/VHH(T)] from the first (Clone 2E3) and the
third (Clone IA3) single-cell sortings, as well as from the
FHR4-free control bifunctional heteromultimers [VHH
(T), clone B2] (10 µgmL1 in 10 mM of acetate buffer,
pH 4.5), was immobilised onto the separate flow paths.
The mock activated–deactivated reference channel was
treated with the amine coupling kit without ligand.
Increasing serial concentrations of C3b (2.5, 5, 10 and
20 µgmL1 in HBS-EP buffer supplemented with
20 mM MgCl2) were successively injected into the differ-
ent flow paths for 5 min at 30 µLmin1, followed by 5-
min dissociation. The surfaces were regenerated after
each cycle with a 15-s pulse of SDS 0.05% at
20 µLmin1. Kinetic curves were mock subtracted,
then the means for each concentration curve, the zero
concentration curve and the corresponding reference
curve were subtracted. The curves were fit with a 1 : 1
Langmuir model to determine the corresponding kA and
kD. The kinetics analysis was conducted with the
BIAevaluation software v4.1 (Biacore 3000; GE Health-
care).
2.8. SDS/PAGE, SYPRO Ruby protein gel
staining and western blotting analysis
One microgram of each of the purified heteromultimers
was diluted in Laemmli sample buffer (Bio-Rad Labora-
tories) and analysed under nonreducing or reducing
conditions (10% of b-mercaptoethanol; Sigma-Aldrich)
using SDS/PAGE (4–15% gradient precast gels; Bio-
Rad Laboratories) followed by SYPRO Ruby protein
gel staining according to the user’s manual (Thermo
Fisher Scientific). The SYPRO Ruby-stained gels were
scanned using the Typhoon Trio imager (laser 488 nm,
filter 610/BP30; GE Healthcare Laboratories) and the
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TYPHOON SCANNER CONTROL v5.0 software (Amersham/
GE Healthcare, Chicago, IL, USA). For western blot-
ting (WB), 50 ng of the proteins was analysed by SDS/
PAGE under nonreduced or reduced conditions and
then transferred to a 0.2-µm polyvinylidene fluoride
membrane (GE Healthcare). Membranes were blocked
in 5% nonfat dried milk in PBS at room temperature
for 30 min. Membranes were probed overnight at 4 °C
with primary antibodies in the same blocking buffer.
Membranes were washed with PBS containing 0.01%
Tween (PBS-T) and probed with the secondary antibody
(when the primary antibody was not already conjugated
to HRP in PBS-5% milk at room temperature for 1 h).
Membranes were washed three times in PBS-T for
10 min before being revealed with the enhanced chemi-
luminescence solution (Western Lightning Ultra Chemi-
luminescent Kit, Perkin Elmer, Zaventem, Belgium).
Chemiluminescence signals were captured using an ECL
CHEMOCAM PHOSPHO IMAGER and the CHEMOSTAR IMAGER




Peripheral blood mononuclear cells (PBMCs) from
healthy donors (Luxembourg Red Cross) were purified
using LymphoPrep solution (Elitech Group BV, Zot-
tegem, Belgium) with density gradient centrifugation at
800 g for 30 min. PBMCs were incubated for 2 h in
complete RPMI medium. Adherent cells were washed
with Dulbecco’s PBS at 37 °C and incubated for
14 days at 37 °C with 5% CO2 in complete RPMI med-
ium supplemented with M-CSF (50 ngmL1). M-CSF
was replaced every 3 days. Monocyte-derived M2
macrophages were trypsinised and plated into Lab-Tek
8-chamber slides (Nunc; Thermo Fisher Scientific).
Forty-eight hours later, macrophages were stained with
PKH26 (Sigma-Aldrich) according to the manufac-
turer’s instructions. BT474 target cells were stained with
CFSE (Invitrogen, ThermoFisher) and then incubated
for 30 min with 20 µgmL1 of (a) combined FHR4/
VHH(T) and FHR4/VHH(P) multimers; (b) combined
trastuzumab and pertuzumab mAbs; or (c) without mul-
timers nor mAbs in GVB++ supplemented with 25%
∆C5HS, heat decomplemented or not. CFSE-stained
complement-coated tumour cells were then washed and
added to the KHP26-stained M2 macrophages (ratio of
BT474 to M2 was 2 : 1) and incubated for 18 h at
37 °C/5% CO2 in complete RPMI medium. Cells were
fixed with 1% PFA, stained with DAPI and analysed
with confocal microscopy as described in section 2.7.
Three series of 10 pictures were taken for each
experimental condition. Phagocytosis was evaluated on
400 macrophages for each condition by counting the
percentage of phagocytic macrophages 22 h after the
beginning of the phagocytosis assay. Statistical analyses
were performed using GRAPHPAD PRISM 5.0 (GraphPad
Software, San Diego, CA, USA), applying analysis of
variance (ANOVA) tests and followed by Dunnett’s
multiple comparison test. Significance was accepted
when P values were < 0.05.
2.10. Analysis of the solution-phase complement
activation
To analyse whether the FHR4-heteromultimeric
immunoconjugates consume complement in the solu-
tion phase, a CH50 test was performed to measure
the 50% haemolytic complement activity of serum
(Costabile, 2010). Sheep red blood cells [50 µL red
blood cell (RBC)mL1 PBS or 2.8108 RBCmL1]
were sensitised with a rabbit haemolytic anti-sheep
erythrocyte serum (dilution 1/15 000) for 30 min at
4 °C. A mix of 90% NHS diluted in 10% GVB++
(90% NHS/10% GVB++) was used as source of com-
plement in the CH50 assay. The relationship between
the amount of complement used and the amount of
RBC lysed is nonlinear but follows a sigmoidal curve.
Thus, for precise measurements of the haemolytic
activity of complement, a titration of 90%NHS/10%
GVB++ dilutions in PBS was established and an end-
point of optimal serum dilution was chosen in the
upper linear part of the curve, before the plateau is
formed to avoid working in excess of complement. In
our experimental design, a dilution of 1/50 of the
90%NHS/10%GVB++ serum corresponding to 75%
haemolysis meets the optimal conditions. Then, two-
fold serial dilutions (starting concentration being
0.8 gL1) of FHR4/VHH(T), FHR4/VHH(P), VHH
(T) heteromultimeric immunoconjugates, trastuzumab,
pertuzumab antibodies used individually or in combi-
nation were incubated for 1 h at 37°C in 90% NHS/
10% GVB++. A serial dilution of aggregated IgG was
prepared in parallel as positive control for phase
solution complement consumption. The blank and
tubes for spontaneous and total lysis were prepared
with SSE alone, or SSE diluted in PBS or water,
respectively. The different sera were diluted 1/50 in
PBS and were incubated with SSE for 30 min at
37 °C. After centrifugation, the supernatants were
collected and the absorbance of the samples was read
at 416 nm. The % lysis for each sample was calcu-
lated using the following formula: [(OD416 (sam-
ple)  OD416 (Blank))/(OD416 (total lysis)  OD416
(Blank))] 9 100.
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3. Results
3.1. Structure–function relationship between
FHR4 valence and AP activation on HER2-
overexpressing tumour cells
Directing local complement activation towards unde-
sired cells (e.g., tumour cells) is an attractive, but
challenging, approach (Carter and Lieber, 2014; Die-
bolder et al., 2014). We hypothesised that multimerisa-
tion of AP effectors at the surface of target cells using
the C4bp C scaffold could achieve this goal. We first
produced a trifunctional heteromultimer displaying (a)
FHR4; (b) the 2D3 anti-HER2 VHH recognising a
trastuzumab-competing epitope [FHR4/VHH(T)]
(Patent US12744991); and (c) eGFP (Fig. S1). Bifunc-
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Fig. 1. The mean FHR4 valence on HER2 cells correlates with AP activation levels and subsequent amounts of C3b deposition. (A) The mean
FHR4 valence of four FHR4/VHH(T) trifunctional heteromultimer-containing supernatants from four different cell clones was analysed by flow
cytometry using SK-OV3 cells and His and eGFP staining. Supernatants containing VHH(T).FLAG (clone F10) or VHH(T).His (clone B2) control
bifunctional heteromultimers – lacking FHR4 – and displaying 0-time (lowest) and seven-time (highest) His, respectively, were used to establish
a calibration curve according to their His MFI/eGFP MFI ratios. Since the FHR4 complement effector- and the VHH anti-HER2 TaFs are
coexpressed within the trifunctional heteromultimers, the global valence of both functions is seven. FHR4 valence within the multimers varies
thus from 1 (and 6xVHH) to 6 (and 1xVHH). The third eGFP TrF is a single molecule within the multimers, and the His tag is on the same arm as
FHR4 (but not the VHH), thus the His MFI/eGFP MFI ratio represents the mean FHR4 densities on SK-OV3 cells. For each clone, the His MFI/
eGFP MFI ratio is reported on the calibration curve, allowing evaluation of the mean FHR4 valence on the y-axis. Note that the multimers in the
supernatants are at saturating concentrations. On the right, SDS/PAGE and SYPRO Ruby protein gel staining depicts the molecular species
from 1x to 5xFHR4 and showed that clone F10.B1 displayed molecular species with higher FHR4-valences as compared to A1 or F10.B2. The
bold line separates lanes from different gels. (B, C) FHR4 multimer-mediated C3b deposition correlates with FHR4 densities on BT474 cells. His
MFI of each clone and controls was measured (B) and was compared to the levels of C3b deposition (C). For F10.B8 and F10.B1, a FHR4
increase by factor 1.15 leads to a C3b increase by factor 1.9. Data are presented as mean values  SD of n = 3 independent experiments.
Statistical analysis was performed using a two-tailed paired t-test. *P < 0.05, **P < 0.01 and ***P < 0.001.
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(Fig. S1) with either a FLAG tag (Clone F10) or a His
tag (Clone B2). Clone F10 was further transfected with
the FHR4 construct to generate trifunctional hetero-
multimers. His/eGFP MFI ratios of four representa-
tive clones with different FHR4 valences are depicted
in Fig. 1A and spanned between the His/eGFP MFI
ratios of the bifunctional heteromultimers, Clones F10
(0.17) and B2 (15.75), correspond, respectively, to a
mean 0xHis and 7xHis on the y-axis of the calibration
curve (Fig. 1A, left). A SYPRO Ruby protein gel
staining analysis (Fig. 1A, right) confirmed that multi-
mers with higher FHR4 valences displayed molecular
species with higher molecular weight (MW) because of
the higher content of FHR4 (120 kDa). The level of
C3b deposition correlated with mean FHR4 valences
within each multimeric clone (Fig. 1B,C). Clones B2
and F10 negative controls (both lacking FHR4) or
trastuzumab did not elicit C3b activation on BT474
tumour cells expressing HER2 (Fig. 1C). The low
valence FHR4L (Clone A1) showed a weak C3b acti-
vation (234 MFI), whereas high valence FHR4H-medi-
ated C3b deposition was more than 10 times higher
than clones B2 or F10 and 5.6 times higher than
FHR4L (1303 vs 234 MFI, respectively). FHR4 stoi-
chiometry within the multimeric immunoconjugates is
therefore the key element to modulate FH-mediated
C3-convertase decay and FHR4-induced AP activa-
tion.
When comparing the ‘high-FHR4 valence group’
that include clones F10.B1/FHR4H & F10.B8 to the
‘low-FHR4 valence group’ that include clones F10.B2
& A1/FHR4L, a respective increase of mean FHR4
densities of 1.15 (FHR4 MFI ratio F10.B1/
F10.B8 = 9246/8000) and 2.93 (FHR4 MFI ratio
F10.B2/A1 = 5700/1947) led to an increase of C3b
deposition of 1.88 (C3b ratio F10.B1/F10.B8 = 1303/
692) and 2.28 (C3b ratio F10.B2/A1 = 535/234),
respectively. These results of FHR4 MFI ratios for the
high- and low-FHR4 valence groups were divided by
the C3b MFI ratios of the same groups, respectively
(1.15/1.88 and 2.93/2.28, respectively). This ratio is
inversely proportional to the efficacy of C3b deposi-
tion relative to the increase of mean FHR4 densities.
The ratio was 0.61 and 1.285 for the high and low-
FHR4 valence groups, respectively. This indicates that
AP activation is twice more efficient in the high-FHR4
valence group than in the low-FHR4 group and twice
as much FHR4 density increase is required in a first
phase of AP activation as compared to the later phase
– when AP activation is already engaged – to lead to
an equivalent C3b deposition efficacy.
A similar approach was used to generate a trifunc-
tional heteromultimer displaying the 47D5 anti-HER2
VHH recognising a pertuzumab-competing epitope
[FHR4/VHH(P)] (Patent US12744991).
3.2. Selection of high-FHR4 valence
immunoconjugates using sequential single-clone
sorting
We further assumed that clonal selection might
strongly influence the multimer expression pattern and
should enhance the mean FHR4 valence within
FHR4/VHH(T) trifunctional heteromultimers, espe-
cially when the intracellular expression of monomeric
EFF of a selected clone is initially higher than that of
the monomeric TaF. Clone F10.B1 (FHR4H) display-
ing high-FHR4 valence multimers was sequentially
submitted to three single-cell sortings. Clones 2E3,
2E9 and IA3 were issued from the first, second and
third single-cell sortings, respectively (Fig. S2). C3b
activation on SK-OV3 cells increased by factors of
1.48 for Clone 2E3, 1.85 for Clone 2E9 and 2.32 for
Clone IA3 at saturating multimer concentrations
(240 nM) when compared with the original F10.B1
clone (Fig. 2A). SPR was used to confirm enhanced
C3b binding capacity of purified FHR4-multimers
from clone IA3 (issued from the third single-cell sort-
ing) when compared to clone 2E3 (issued from first
single-cell sorting; Fig. 2B). We observed no C3b
binding either on the FHR4-free B2 control multimer-
coated surface or on reference surface without multi-
mer (data not shown). At 20 µgmL1 of injected
C3b, the maximum C3b binding for Clone IA3 was
higher than for Clone 2E3 (136 vs 100 RU, respec-
tively), and the final C3b binding was similarly
enhanced by a factor of 1.36 (78.6 vs 58 RU, respec-
tively; Fig. 2C). The calculated equilibrium association
constants (KA) were 3.65 9 10
6
M
1 for Clone 2E3
and 4.48 9 106 M1 for Clone IA3. The equilibrium
dissociation constants (KD) were 2.74 9 10
7
M for
Clone 2E3 and 2.23 9 107 M for Clone IA3, respec-
tively, showing a similarly high affinity of the
immunoconjugates for C3b. The dose–response rela-
tionship between FHR4 density and AP-activation
efficacy was compared between the optimised high-
FHR4 valence (IA3) and the initial low-FHR4 valence
(A1) heteromultimers (Fig. 2D). At saturating and
similar concentrations of each multimer (Fig. 2D,
right), FHR4 densities were five times higher for IA3
(72 953 MFI) than for A1 (14 487 MFI; Fig. 2D, left).
Subsequent C3b activation was seven times higher for
IA3 (37 541 MFI) than for A1 (5432 MFI) multimers
(Fig. 2D, middle). A detailed analysis of the dose–re-
sponse of multimer-mediated AP activation high-
lighted that the IA3 concentration of 0.8 µgmL1,
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corresponding to an MFI of 26 496 for FHR4
(Fig. 2D, left), represents the critical FHR4 density to
enable efficient AP activation (Fig. 2D, middle). Fur-
ther linear increase beyond this critical density, and up
to 20 µgmL1, coincides with a linear increase of C3b
deposit, inflecting from 7.5 µgmL1 IA3 multimers,
and establishing a plateau with a final MFI of 72 953
for FHR4. In contrast, for A1 multimers, FHR4 den-
sities reached a plateau from a starting concentration
of 5 µgmL1, with a maximal MFI of 14 487,
representing only 55% of the FHR4 density required
to start activating AP. High FHR4 valence multimer-
mediated C3b activation appeared to occur on target
cells according to a bimodal reaction. The first phase
takes place below the complement inhibitory threshold
(CIT; Fig. 2D, middle) when FHR4 density cannot
fully compete with FH. The second phase corresponds
to the phase above the CIT, where FHR4 densities are
sufficient to counteract FH-controlled complement
inhibition.
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Fig. 2. Sequential single-cell sorting allowed the selection of cell clones expressing multimers with enhanced FHR4 mean valence and
improved AP activation efficacy. (A) FHR4/VHH(T) trifunctional heteromultimer-containing supernatants from clones F10.B1 (FHR4H) and
those after three sequential cell sortings (2E3, 2E9 and IA3, respectively) showed increased FHR4 mean valence which correlates with an
increase of MFI for C3b of a factor 2.32 between FHR4H and IA3. (B) Surface plasmon resonance analysis showed higher C3b binding
specificity for FHR4 between the 1st (clone 2E3) and the 3rd (clone IA3) cell sorting. Sensorgrams for 2E3 (left) and IA3 (right) are depicted.
(C) C3b binding increased of a factor 1.35 between captured 2E3 and IA3 multimers (58 and 78 RU for 2E3 and IA3, respectively) was
observed which correlates with increase mean FHR4 valence within multimers. (D) C3b activation takes place according to a bimodal
reaction only for the high FHR4 IA3 clone but not the low-FHR4 A1 clone. At same multimer densities on SK-OV-3 cells (right graph), only
FHR4 densities from clone IA3 – but not from clone A1 – (left graph) succeeded in overcoming the CIT (middle graph), the critical point
where the competition of FHR4 with FH for C3b is strong enough to inhibit FH and to subsequently engage efficient AP-positive
amplification loop, leading to a linear increase of C3b deposition (phase 2 in the middle graph).
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We next used SDS/PAGE combined either with
SYPRO Ruby protein gel staining or with WB to anal-
yse the molecular pattern of the optimised immuno-
conjugates after clonal selection. Under nonreducing
conditions, SYPRO Ruby staining (SRS) showed that
the bifunctional Clone B2 (Fig. 3A, lane 4) displayed
two main bands, corresponding to the molecular
species 7xVHH/1x eGFP and 6xVHH/1x eGFP. A
third lower minor band may correspond to a hexam-
eric form lacking the eGFP b chain. The A1 multimer
molecular pattern (Fig. 3A, lane 3) displayed two main
bands that correspond to molecular species with 1x
and 2xFHR4, respectively. 2E3 multimers (Fig. 3A,
lane 1) displayed six bands that correspond to
2E3 IA3 A1 B2
250
WB - NR an-FHR4 an-FLAG












































































Fig. 3. Analysis of the molecular patterns of purified A1, 2E3 and IA3 multimers using SRS or WB with anti-FHR4, anti-His or anti-Flag
antibodies under nonreducing conditions (NR, A, B, C) or under reducing conditions (R, D, E). (A, B) IA3 multimers display molecular species
with higher FHR4 valences than their 2E3 counterparts. A1 low-FHR4 valence multimers display two main bands that correspond to 1x and
2xFHR4 molecular species. B2 control multimers display two lower bands, both lacking FHR4, and corresponding to the 7a1b and 6a1b
molecular species, with the VHH anti-HER2 and eGFP functions being fused to C4bpa and C4bpb, respectively. A lower third band, much
less represented (~ 6% of the total), could correspond to a multimeric molecular species lacking eGFP function. (C) The percentages of
each molecular species within the 2E3, IA3 and A1 multimers are shown by using the method of the calculation of the area under the
curve. (D) SRS under reducing conditions showed each function as a monomer: FHR4, VHH anti-Her2 and eGFP of 120, 40 and 50 kDa
molecular weight, respectively. The band corresponding to FHR4 is absent for clone B2 which lacks FHR4 function. (E) WB under reducing
conditions. Using the anti-His Ab, FHR4.C4bpa.His8x function was illuminated for 2E3, IA3 and A1, but not B2 which lacks FHR4 (e left).
Instead, the 2D3 VHH.C4bpa.His function was revealed in B2 (e left, lane 4). At same protein concentration, the band was stronger for IA3
– when compared to 2E3 and A1 – which harbours higher FHR4 valence. When using the anti-FLAG Ab, the VHH anti-HER2.C4bpa.FLAG
function was revealed for 2E3, IA3 and A1, but not B2, which harbours a His tag.
2540 Molecular Oncology 13 (2019) 2531–2553 ª 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
FHR4-multimers activate complement on tumour cells C. Seguin-Devaux et al.
molecular species with 1x to 6xFHR4 valences, includ-
ing two main bands for 1xFHR4 and 3xFHR4 valence
molecular species. When compared with 2E3, IA3 mul-
timers (Fig. 3A, lane 2) displayed: (a) more molecular
species with 4x, 5x and 6xFHR4 valences; and (b less
molecular species with 1x and 2xFHR4 valence. A WB
analysis under nonreducing conditions (Fig. 3B) con-
firmed the molecular patterns depicted by the SYPRO
Ruby protein gel staining analysis when revealed with
either the anti-His or the anti-FHR4 antibody
(Fig. 3B). The analysis showed 3xFHR4 to 6xFHR4
molecular species for IA3 (Fig. 3B, lane 2) that were
absent in 2E3 (Fig. 3B, anti-His, lane 1). A FLAG
analysis showed a stronger intensity for A1 than for
2E3 or IA3, in agreement with higher VHH anti-HER2
valence in A1 (Fig. 3E). The proportion of each
molecular species was determined by measuring the
area under the curve for each peak of the different
clones detected by the SYPRO Ruby protein gel stain-
ing analysis (Fig. 3C). Overall, a clear shift towards
molecular species with higher FHR4 valence for IA3
was revealed, while a shift towards lower FHR4
valences was observed for A1. A 2.5 times higher
FHR4 valence for IA3 than for the A1 multimers was
observed, as well as a 1.4 times higher FHR4 content
in IA3 than in 2E3, in accordance with C3b binding
(factor 1.35, Fig. 2C) and C3b deposition (factor 1.6,
Fig. 2A) enhancements. The SRS analysis under reduc-
ing conditions (Fig. 3D) showed three bands that cor-
respond to the monomeric forms of
FHR4.C4bpa.His8x, the eGFP.SCR3.C4bp b and the
VHH anti-HER2.C4bpa.FLAG, respectively, for each
clone. WB analysis under reducing conditions
(Fig. 3E) revealed stronger intensity of FHR4 (His
antibody) for Clone IA3 as compared with Clones 2E3
and A1 (Fig. 3E, left, lane 2) and a similar expression
of the VHH anti-HER2 (FLAG antibody, Fig. 3E).
3.3. Optimised FHR4 immunoconjugates with
enriched molecular species promote enhanced
C3b depositions, MAC binding and CDC
We performed a His-Trap purification of the FHR4-
high valence trifunctional heteromultimers with either
trastuzumab-competing [FHR4/VHH(T)] or per-
tuzumab-competing [FHR4/VHH(P)] anchoring moi-
eties using a 3-step sequential elution (Fig. S3) to
further enrich in molecular species with higher FHR4-
valence. The SYPRO Ruby protein gel staining and
WB analyses showed that low-FHR4 valence multi-
mers, as well as irrelevant contaminants, were in the f1
fractions (Fig. 4A left), while f2 and f3 displayed
increasingly enriched molecular species with higher-
FHR4 valence. The analysis of mean FHR4 valence,
AP activation and CDC on BT474 cells of f1 to f3
fractions of FHR4/VHH(P) His-Trap purifications
(Fig. 4C) showed a strong linear correlation between
mean FHR4 valence and C3b deposition (r2 = 0.94)
and between C3b deposition vs CDC (r2 = 0.99;
Fig. 4D). An increase of mean FHR4 valence of a fac-
tor 1.33 from f1 to f3 fractions led to an increase in
deposited C3b by a factor of 3.8, consequently leading
to an increase of cell death from 38% to 65% (factor
1.7; Fig. 4B,D). Since the difference of multimer-in-
duced CDC is narrow, for each FHR4/VHH(T) and
FHR4/VHH(P) multimers, f2 and f3 fractions were
pooled for further analyses and represented the lead
FHR4/VHH(T) and FHR4/VHH(P) multimers that
were used for the further experiments.
We further tested FHR4/VHH(T) and FHR4/VHH
(P) multimeric immunoconjugates either individually
or in combinations in three different cell lines express-
ing HER2 (SK-OV3, BT474 and SK-BR3 cells) for
CDC (Fig. 5A), C3b deposition (Fig. 5B) and MAC
binding (Fig. 5C). In SK-OV3 cells, trastuzumab- and
pertuzumab-mediated CDC was poor when used indi-
vidually (20–27% lysis), whereas 93% of cell death
was achieved when both antibodies were combined.
Most of SK-OV3 cells were lysed by FHR4/VHH(T)
(95%) or FHR4/VHH(P) (91%), reaching lysis of 97%
when combined. For BT474 cells, cell lysis was 60%,
40% and 77% for FHR4/VHH(T), FHR4/VHH(P) and
their combination, respectively, as compared to 21%
lysis when using combined trastuzumab and per-
tuzumab. The combination of FHR4/VHH(T) with
pertuzumab led to a CDC close to that of combined
FHR4/VHH(T) + FHR4/VHH(P) heteromultimers
(69% vs 76% cells death). In contrast, the other com-
bination between trastuzumab and the FHR4/VHH(P)
was significantly less efficient (P = 0.0006). For SK-
BR3 cells, only the combination of FHR4/VHH(T)
and FHR4/VHH(P) led to a cell lysis of 57% and the
combination of FHR4/VHH(T) and pertuzumab led to
39% cell lysis. Of note, the control multimer VHH(T)
displayed some cell death (30%, 13% and 20% on
SK-OV3, BT474 and SK-BR3, respectively) in a com-
plement-independent fashion, since cell death remained
unchanged when using decomplemented NHS (data
not shown).
In SK-OV3 cells, levels of C3b deposition were
highly correlated with CDC for all conditions used
(Fig. 5A,B) but not with MAC binding, suggesting
that a certain threshold amount of MAC densities was
able to induce CDC in these cells. Regarding BT474
and SK-BR3 cells, the efficacy of C3b deposition cor-
related well with CDC when the multimers were used
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alone but not when combined with mAbs (Fig. 5A,B):
for the same levels of C3b deposition, CDC was about
twice as low for combined mAbs than for FHR4 mul-
timers. For BT474 cells, similar C3b MFI led to 20%,
60% and 43% cell lysis when using combined mAbs,
FHR4/VHH(T) or FHR4/VHH(P), respectively. For
SK-BR3 cells, combined mAbs, or a combination of
FHR4/VHH(T) and pertuzumab displayed C3b MFI
of 7024 and 5265, whereas percentages of cell death
were 23% and 40%, respectively. A clear correlation
was observed between MAC binding and CDC for
FHR4-based multimers and FHR4-based multimers in
combination with mAbs in BT474 and SKBR3 cells as
depicted in Fig. 5B,C, but not for combined mAbs.
The two most favourable conditions for highest MAC







































Correlation between C3b deposits, FHR4 densities and CDC on BT474 
mediated by purified FHR4/VHH(P) multimer fractions 














































Fig. 4. FHR4/VHH(T) or FHR4/VHH(P) multimer-containing cell culture supernatants were purified using His-Trap and FPLC chromatography
and a three-step elution was then performed. The first step using 120 mM imidazole, the 2nd and 3rd steps using 1 M imidazole with an at
least 2 h-stop in-between the last two steps. Pooled collected fractions from each step are called f1, f2 and f3, respectively. (A) SRS
analysis of f1–f3 fractions of purified FHR4/VHH(T) or FHR4/VHH(P) multimers under nonreducing (NR; left) and reducing (R; right) conditions.
f1 contains mainly low-FHR4 valence molecular species (1x and 2x FHR4), as well as contaminants. f2 and f3 display relative similar
patterns, with higher FHR4-valence molecular species, notably 3x–6xFHR4. Under reducing conditions, top-down reduced bands (arrows)
correspond to FHR4.C4bpa.His, eGFP.C4bpb, VHH(T).C4bpa.FLAG and VHH(P).C4bpa.FLAG monomers, displaying apparent MW 120, 50, 40
and 33 kDa, respectively. (B) WB analysis under NR of f1 and f3 from FHR4/VHH(T) or FHR4/VHH(P) multimers using a mouse anti-human
FHR4 mAb confirmed the SRS analysis; f1 fractions contain lower FHR4-valence molecular species. (C, D) Correlation between C3b
deposition, mean FHR4 densities and CDC on BT474 cells mediated by purified FHR4/VHH(P) multimer fractions. BT474 cells were
incubated with saturating concentrations of f1 to f3 (20 µgmL1) from two different FHR4/VHH(P) purifications, then with 30% NHS at
37 °C. Cells were analysed by flow cytometry for mean FHR4 densities, C3b deposition and CDC. (C) Correlation between mean FHR4
densities and C3b deposition. (D) Correlation between the percentage of dead cells (i.e., live/dead-positive cells) and C3b deposition. The
black dot represents the comparison with the use of combined trastuzumab and pertuzumab, showing the same range of C3b deposition as
f3, but a far weaker cell death.
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Fig. 5. Multimer/mAb-mediated CDC (A), C3b deposition (B) and MAC formation (C) on SK-OV3, BT474 and SK-BR3 tumour cell lines.
Optimised FHR4/VHH(T), FHR4/VHH(P) trifunctional heteromultimers, control VHH(T) bifunctional heteromultimer, and trastuzumab and
pertuzumab were tested individually or in combination at saturating concentrations (20 µgmL1), and incubated with 30% NHS at 37 °C for
30 min. Negative controls are control multimers [VHH(T)] and NHS alone. (A) Cells were stained with live/dead. Percentages of dead cells
(live/dead-positive cells) were analysed using flow cytometry. (B) Cells were stained with an anti-C3b mAb (clone 7C12) followed by an anti-
mouse IgG PE-conjugated pAb. (C) Cells were stained with an anti-C5b-9 mAb (clone aE11) followed by an anti-mouse IgG PE-conjugated
pAb. Data are presented as mean values  SD of n = 3 independent experiments; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
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combination with the two FHR4-based multimers and
the combination of FHR4/VHH(T) with pertuzumab
(Fig. 5B). For the three studied cell lines, combined
FHR4-multimers elicited more than twice MAC densi-
ties than when used individually. In contrast, mAbs
used alone as well as the VHH(T) control multimer eli-
cit strictly no MAC binding. This reinforces the fact
the VHH(T) control multimer-mediated cytotoxicity
mainly observed for SK-OV3 is not dependent upon
complement activation.
Multimer-mediated C3b deposition and CDC were
further confirmed on BT474 cells using serial dilutions
(Fig. S4A,B). C3b deposition and CDC were sustained
at lower multimer concentrations when FHR4/VHH(T)
and FHR4/VHH(P) multimers were combined than
when they were used individually. Although the
FHR4/VHH(T) and pertuzumab combination led to
the highest C3b deposition and strongest CDC at the
highest multimer concentration, the drop in the
amounts of C3b deposition and related CDC were
much faster than for combined FHR4/VHH(T) and
FHR4/VHH(P) multimers, suggesting that pertuzumab
reinforced the effect of FHR4/VHH(T) on AP activa-
tion and CDC only at highest concentrations.
We next showed that the addition of FH lowered in
a dose–response manner FHR4 enhancing effect on
AP activation and subsequent C3b depositions on
HER2-overexpressing tumour cells (Fig. S4C). These
data support that FH antagonised the C3b deposition
mediated by the FHR4-based immunoconjugates.
Finally, to explain the diverse resistance to comple-
ment attack among the three different cell lines used,
we measured the relative mCRP (Fig. 6A,C) and
HER2 densities (Fig. 6B,C) on the three cell lines by
flow cytometry. SK-OV3 cells expressed about twice as
much HER2 (displayed as MFI values) and lower
CD46/CD55 densities compared to the two other cell
lines, followed then by BT474 cells, in accordance with
their increased resistance to complement attack as
observed in section 3.3. SK-BR3 cells were the most
resistant cell line, displaying 5–10-times more CD55
densities and 1.4–2.8-times more CD59 densities than
SK-OV3 and BT474 cell lines.
To finally assess whether the FHR4-heteromulti-
meric immunoconjugates activate the alternative (AP)
vs the classical (CP) pathways, C3b and C4d deposi-
tion was measured in six different conditions (Fig. S5).
In conditions 1 (NHS/GVB++), 5 (∆FBHS + FB) and
6 (∆C5HS), both AP and CP were functional, and C3b
deposition was therefore observed when using com-
bined FHR4-multimers or combined mAbs, whereas
C4d deposition was observed only when using com-
bined mAbs and not FHR4-multimers. In conditions 2
(NHS/GVB+) and 3 (∆C1qHS), only the AP was func-
tional: the combined FHR4-multimers induced C3b
but no C4d deposition. In contrast, when the CP was
only functional and not the AP in condition 4
(∆FBHS), only the combined mAbs induced C3b as
well as C4d deposition and not the combined FHR4-
based immunoconjugates. When FB was added (condi-
tion 5), the C3b amplification loop (AP) was restored.
Consequently, C3b deposition, but no C4d deposition
was observed when using combined FHR4-multimers
(Fig. S5A,B).
3.4. Optimised FHR4-immunoconjugates induce
MAC binding on membrane and promote specific
complement-dependent macrophage-mediated
phagocytosis of BT474 target cells
We used confocal microscopy to visualise MAC
binding and examine the colocalisation between the
immunoconjugates and C3b or C5b-9 on the surface
of BT474 cells. FHR4/VHH(T) immunoconjugates
(green) were relatively homogeneously distributed on
the surface of the cells, displaying a strong colocali-
sation with the C3b deposition (red; Fig. 7A, third
and fourth merged pictures) resulting in a yellowish-
orange colour. The C5b-9 staining was, in contrast,
much more dispersed and clustered than C3b stain-
ing with many bright red spots detected (Fig. 7B,C),
indicating that MAC is mainly assembled further
away from the multimers and at lower densities than
C3b deposition. The magnification of a cell in
Fig. 7C shows that the yellowish-orange interface
seems to span across the green staining and through
the membrane. Bright red spots in Fig. 7C are visi-
ble either on top of or through a yellowish-orange
interface and sometimes make protrusions through
the membrane and extend slightly towards the inside,
which may represent MAC that are anchored
through the membrane. When using decomplemented
serum, we did not observe any C3b or C5b-9 stain-
ing as depicted in Fig. 7D. Interestingly, we detected
green multimer staining inside the cells in Fig. 7A–
C. This intracellular staining indicated an endocyto-
sis of HER2-multimeric complexes, which are partic-
ularly visible when using the FHR4-free B2
multimers harbouring 7xVHH anti-HER2 valences
(data not shown), which occurs in a complement-in-
dependent manner.
We further evaluated multimer-directed CDCP using
effector monocyte-derived M2-macrophages on BT474
tumour cells (Fig. 8A,B). Used individually, both
FHR4/VHH(T) multimers and trastuzumab induced
about 10% phagocytosis above control serum
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Fig. 6. mCRP (A) and HER2 (B) relative densities in SK-OV3, BT474 and SK-BR3 tumour cell lines as determined by flow cytometry. (A)
CD46-APC, CD55-PE and CD59-FITC Abs were coincubated with the cells lines. (B) Trastuzumab was incubated at saturating concentrations
with the cells and its binding was revealed with an APC-conjugated anti-human IgG. (C) Dot plot representation of CD46, CD55, CD59 and
HER2 MFI on SK-OV3, BT474 and SK-BR3 HER2-overexpressing tumour cell lines. Data are means  SD of three experiments.
2545Molecular Oncology 13 (2019) 2531–2553 ª 2019 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
C. Seguin-Devaux et al. FHR4-multimers activate complement on tumour cells
Fig. 7. Confocal microscopy analysis of FHR4/VHH(T) multimer-mediated C3b deposition and MAC formation on BT474 cells. (A)
Colocalisation of C3b deposition and FHR4/VHH(T) multimeric immunoconjugate (clone IA3). IA3 multimers on the cell surface (green) and
C3b staining (red) were merged as a one-layer section. A strong colocalisation appears as yellowish-orange staining. The far right image is a
3D merging that represents whole cells. The scale bars represent 10 µm. (B) MAC formation analysis. FHR4/VHH(T) Multimer (green) and
C5b-9 staining (red) were merged as one-layer sections (third picture from left), or as a reconstruction of 3D stacked-up one-layer sections.
Bright red spots were revealed with some colocalisation with the multimers as the yellow interface. The scale bars represent 10 µm. (C)
Magnification of a single cell representing the details of inserted MAC. The magnification of a single section of a merged staining from (B),
showing the C5b-9 staining of a one-layer section (left), or a 3D reconstruction of merged staining (right). The scale bars represent 5 µm.
(D) 3D reconstruction of sections with merged multimer and C3b (left) or C5b-9 staining (right) in conditions where decomplemented NHS
was used showed no staining. The scale bars represent 5 µm.
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indicating that the phagocytosis taking place through
Fc-FccRs interactions (ADCP) was as efficient as the
phagocytosis taking place through C3b breakdown
products, which is in accordance with previous data
(Lee et al., 2017). In contrast, pertuzumab and the
FHR4/VHH(P) multimers did not elicit macrophage-
mediated phagocytosis. The combination of the two
FHR4 multimers [FHR4/VHH(T) + FHR4/VHH(P)] or
the mAbs (trastuzumab + pertuzumab) did not further
increase phagocytosis. The highest percentages of
phagocytic macrophages were observed when combina-
tions of (a) pertuzumab with [FHR4/VHH(T)] (40%
phagocytosis); or (b) trastuzumab with [FHR4/VHH
(P)] (33% phagocytosis) were applied. In Fig. 8B left,
the picture depicts phagocytic macrophages that are
marked by arrows. One or more green-stained BT474
cells are clearly visible within the red-stained phago-
cytic macrophages. Figure 8B right depicts a magnifi-
cation of a phagocytic macrophage with its blue
nucleus, which shows one or more degraded BT474
cells including debris visible in green.
3.5. Solution-phase complement activation
To determine whether the FHR4-heteromultimeric
immunoconjugates could spontaneously activate com-
plement in the extracellular fluid phase before they
reach their targets, we analysed the immunoconjugate-
mediated soluble phase complement using a CH50
assay (Fig. S6). When sheep erythrocytes previously
sensitised with a rabbit haemolytic anti-sheep erythro-
cyte serum are incubated with serum, the complement
CP is activated and haemolysis takes place. If the com-
plement in the serum is absent, the CH50 will be zero;
if one or more complement components of the CP (in-
cluding C3) are decreased, the CH50 will be propor-
tionally decreased. Figure S6A depicts the titration of
the serum and the calibration curve for the CH50
assay, with a dilution 1/50 in PBS to reach 75% lysis
of sensitised sheep erythrocytes as an optimised condi-
tion for the CH50 assay. Figure S6B shows that the
CH50 for the control aggregated IgG is 0.24 gL
1,
while the CH50 for the FHR4-multimers was
0.55 gL1 (36.66 mgkg1). Most therapeutic antibod-
ies are given at doses < 10 mgkg1 (Ryman and Mei-
bohm, 2017), which corresponds to 0.15 gL1. At this
concentration, the soluble phase complement activa-
tion using FHR4-heteromultimeric immunoconjugates
was slightly above that of the therapeutic antibodies
(76% vs 86% haemolysis, respectively), indicating that
the FHR4-heteromultimeric immunoconjugates should
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C5-HS
Fig. 8. Complement-dependent macrophage-mediated phagocytosis
of BT474 cells. (A) CFSE-stained BT474 tumour cells were
incubated with multimers and/or antibodies individually or in
combination. Cells were incubated with 25% C5-deficient human
serum (∆C5HS) to prevent lysis. KPH26-stained monocyte-derived
M2-macrophages were then incubated with tumour cells (ratio 2 : 1)
for 18 h. (A) Percentage of phagocytic macrophages was measured.
Data are presented as mean values  SD out of n = 3 series of 10
confocal images for each condition. Statistical analysis was
performed using a two-tailed paired t-test. *P < 0.05, **P < 0.01,
***P < 0.001. (B) Left: Confocal microscopy images of phagocytosis
of BT474 cells. The white arrows show the phagocytic
macrophages (red) having engulfed BT474 cell(s) and harbouring a
green or yellowish colour. Scale bar represents 50 µm. Right:
Details of a phagocytic macrophage (red) at higher magnification
(609 oil immersion). Since BT474 are poorly adherent,
nonphagocytosed free-BT474 cells are washed away during the
washing step. Scale bar represents 10 µm.
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4. Discussion
In the present study, we showed for the first time that
immunoconjugates expressing multimeric complement-
activating FHR4 and anti-HER2 anchoring moieties
were able to lyse targeted HER2-expressing breast
tumour cells in vitro through CDC using the activation
of the AP. We hypothesised that enhanced local densi-
ties of FHR4 at the surface of target cells are the critical
point that would allow to overcome a CIT at the tumour
cell surface that is established by the mCRP densities
but also by bound FH. We therefore used the C4bp C-
terminal of the a and b chains of the multimerising scaf-
fold (Dervillez et al., 2006; Oudin et al., 2000) to gener-
ate trifunctional heteromultimers, covalently linking (a)
multimeric FHR4; to (b) trastuzumab- or pertuzumab-
competing nanobodies targeting HER2; and to (c) a
monomeric eGFP allowing for the selection of molecu-
lar species with high FHR4-valences.
We showed here that high FHR4 valence is the key
element to trigger efficient AP activation (Figs 2D, 4C,
D and 7A) and to induce MAC binding (Figs 5C and
7B,C), CDC (Figs 5A and S4B) and phagocytosis
(Fig. 8A) on cells expressing HER2. Local densities of
FHR4 on target plasma membranes thus determine
the efficacy of counteracting the regulatory effect of
FH and subsequent AP activation efficacy (Figs 2A,D,
4C,D and S4AB). Only molecular species enriched
with sufficient FHR4 densities through sequential clo-
nal selection and His-Trap selective multistep purifica-
tion succeed in overcoming FH-established CIT on
HER2-tumour cells (Fig. 2D). A linear increase of
FHR4 densities leads to the AP amplification loop
taking place as ‘switch off/on’ biphasic reaction until
the CIT is overcome (Fig. 2D). Multivalent FHR4
expression enhanced FHR4-mediated FH deregulation
and directed local AP activation which led to massive
C3b deposition on target cell surface. The oligomerisa-
tion of FHRs is a common feature for FHR1, FHR2
and FHR5, which display a dimerisation motif in their
N termini allowing the formation of homo and/or het-
erodimers as well as well as tetrameric complexes (van
Beek et al., 2017; Goicoechea de Jorge et al., 2013;
Jozsi et al., 2015). This oligomerisation dramatically
enhances FHR functional avidity in vivo as competi-
tive antagonists of FH. FHR4, however, lacks this
dimerisation motif. The natural homo-dimerisation of
FHR4 to a very low extent might, however, also exist,
as previously reported (Hellwage et al., 1999),
although it has not been shown in vivo. FHRs compete
with FH for C3b, iC3b and C3d binding, but, in con-
trast with FH, FHRs do not have a strong comple-
ment inhibitory effect due to the lack of FH-like
regulatory domains (Jozsi et al., 2015). In particular,
FHR4A lacks FH-like decay accelerating activity for
assembled C3bBb C3 convertases, but may affect C3b
sensitivity to inactivation by factor I (Hebecker and
Jozsi, 2012). FHR4 is unlikely to be of major physio-
logical relevance (Hellwage et al., 1999) because
reported FHR4 plasma concentrations – 25.4 µgmL1
measured by Hebecker and Jozsi (2012) and
2.55 µgmL1 measured by Pouw et al. (2018) using
FHR4A-specific mAbs – are much lower than those of
FH. Under physiological conditions, FHR4 may
slightly reduce FH binding on late apoptotic, necrotic
or senescent cells, thereby allowing enhanced C3b
deposition and subsequent clearance of these opso-
nised cells by host phagocytes. Furthermore, FHR4
may preferentially bind to dead cell or pathogen sur-
face via its interaction with C-reactive protein
(Hebecker et al., 2010; Mihlan et al., 2009), thus weak-
ening FH binding and/or increasing complement acti-
vation on such surfaces.
Alternative pathway activation and C3b deposi-
tions are tightly regulated by soluble- and mem-
brane-associated complement regulators that (a)
prevent the C3/C5 convertase assembly (C4bp, FH,
CD46 and CD55); (b) accelerate the dissociation of
membrane-bound C3/C5 convertases (CD55); and (c)
prevent the assembly of the terminal complement
complexes C5b-9 (CD59) (Jozsi et al., 2015). Overex-
pression of some mCRPs is therefore considered to
be a poor prognostic factor in cancer, whereas
increased iC3b on tumours is a favourable prognos-
tic factor (Liu et al., 2014). Using three different
HER2-tumour cell lines being more or less resistant
to complement attack, we showed that mCRP and
HER2 expression patterns (Fig. 6) further determine
a second level of control on AP expansion and lytic
MAC densities, controlling FHR4-multimer-mediated
CDC efficacy (Fig. 5). The most favourable situation
was found for the SK-OV3 cell line that displays
low mCRP and high HER2 densities (Figs 5, 6 and
S4). We further showed that the combination of the
two optimised FHR4-high valence multimers recog-
nising two distinct HER2-epitopes further enhanced
mean FHR4 densities on cell surfaces and subsequent
AP activation and cell death (Figs 5 and S4). When
using the most complement-resistant tumour cell line
SK-BR3, only the combination of the two optimised
FHR4-high valence multimers succeeded in eliciting
CDC and, to a lesser extent, the combination of per-
tuzumab and the FHR4 multimers with trastuzumab-
competing VHH [FHR4/VHH(T)] (Fig. 5A). Comple-
ment-mediated cell killing of breast, lung and ovarian
tumour cells by combined trastuzumab and
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pertuzumab was previously shown to be efficient only
when all three CD46, CD55 and CD59 mCRPs were
suppressed using the siRNA gene silencing technology
(Mamidi et al., 2013). A comparative analysis of AP
activation by the two combined FHR4-multimers vs
the two combined anti-HER2 therapeutic mAbs
clearly showed that at same levels of C3b deposition,
subsequent MAC densities are far greater and CDC is
up to four times higher when using combined FHR4-
multimers than when using combined mAbs (Figs 5
and S4). These data reinforce previous data hypothe-
sising that the convertases associated with FHR4 are
at least in part protected from FH-mediated decay
when compared to non-FHR4-associated convertases
(Hebecker and Jozsi, 2012). By contrast, the formed
convertases during mAb-mediated CP activation are
not protected from FH- and mCRP-mediated decay,
which leads to sublytic MAC binding and absence or
weak CDC, despite initial massive C3b deposition.
We also confirmed that FHR4-heteromultimeric
immunoconjugates do exclusively activate AP using
the analysis of C3b and/or C4d deposition on SK-OV3
cells in serum conditions where AP, CP or both
AP + CP were functional (Fig. S5). These results vali-
dated our hypothesis that FHR4-heteromultimers, by
competing with FH, subsequently activate the C3b
amplification loop (AP) and thus have no role in the
CP activation. In contrast, combined trastuzumab and
pertuzumab activate the CP, which may have a retro-
control effect on the AP activation (Fig. S5), since
more C3b deposition and less C4d deposition were
observed when AP activity was recovered by the addi-
tion of FB. The advantage of using AP-complement
activators such as FHR4 is that they are not under the
control of additional complement regulators of
upstream pathways such as C1-INH of C4bp that reg-
ulate CP.
To note, the control VHH(T) heteromultimer (lack-
ing FHR4) displayed a certain degree of cytotoxicity
that was independent from CDC, displaying a cell kill-
ing with no C3b deposition in the presence of NHS
(Figs 5A,B and S4A,B), or displaying the same cell
killing in the presence of decomplemented serum
(Fig. 5A), and this effect was more pronounced on
BT474 cells (Fig. 5A). The higher degree of VHH
valences of these multimers in the absence of FHR4
moieties could explain their enhanced ability to cross-
link HER2 receptors on target cell surfaces, when
compared to FHR4/VHH(T) or FHR4/VHH(P) multi-
mers. It has previously been reported that HER2
cross-linking prevents cells from forming signalling-
competent dimers with any EGFR family member,
subsequently preventing any kinase dimerisation, and
thus leading to a complete loss of HER2-signalling
and having an anti-proliferative effect (Jost et al.,
2013). Various human tumour cell lines rely on HER2
signalling for their survival, referred to as ‘HER2-ad-
dicted’ cells (Moasser, 2007). This may explain the
additional cytotoxic effect of the VHH(T) multimer. A
confocal microscopy analysis showed the homogeneous
membrane distribution of FHR4/VHH(T) eGFP-posi-
tive multimers on BT474 cells and a remarkable colo-
calisation with C3b deposition (Fig. 7A). In contrast,
C5b-9 staining is more disseminated, depicting intense
red spots through and on the plasma membranes that
are more distant from FHR4-multimers (Fig. 7B,C).
Importantly, for potential therapeutic application,
nonspecific complement activation by FHR4-hetero-
multimeric immunoconjugates in the extracellular fluid
is not desired as long as the multimers are not bound
to their targets (Fig. S6). Based on a CH50 in vitro
immunoassay, our results indicate that FHR4-hetero-
multimeric immunoconjugates do not mediate signifi-
cant soluble phase complement activation at
concentrations that are commonly used in the clinic
for therapeutic mAbs (Fig. S6B, blue area).
We then investigated the ability of opsonised BT474
tumour cells – upon multimer-mediated complement
activation – to be phagocytosed by monocyte-derived
M2-macrophages, a phenomenon known as comple-
ment-dependent cell-mediated phagocytosis (CDCP)
(Chan et al., 2009; Gelderman et al., 2004) (Fig. 8).
We showed that FHR4/VHH(T) multimers elicit the
phagocytosis of BT474 cells with the same efficacy
than trastuzumab (Fig. 8A). Moreover, we showed
that FHR4/VHH(T) multimers were superior to
FHR4/VHH(P) to support the phagocytosis of BT474
cells, which correlates with the fact that FHR4/VHH
(T) multimers elicit stronger C3b deposition than their
FHR4/VHH(P) multimeric counterparts. Thus, a
higher C3b deposition allowed increased phagocytosis.
The combination of the mAbs or FHR4-multimers
with mAbs led to enhanced phagocytosis efficacy, par-
ticularly the combination of FHR4/VHH(T) hetero-
multimers and pertuzumab (Fig. 8A). This increased
phagocytosis efficacy could be explained by the con-
comitant interactions of Fc-FccRs and iC3b-CD11b/
CD18 between target cell surfaces and macrophages,
which reinforce the strength of physical contact
between BT474 and macrophages, favouring the
macrophage-mediated phagocytosis of BT474 cells.
Beyond CDC and direct cell killing, our data are in
line with the observation that phagocytosis of opso-
nised tumour cells represents a critical mechanism to
eliminate undesired opsonised cells by CDCP (Gelder-
man et al., 2004). The complement breakdown
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products on HER2 cells are recognised by the CD11b/
CD18 (CR3) receptor complex on macrophages (Chan
et al., 2009; Gelderman et al., 2004).
Taken together, the present study showed that
the degree of FHR4-multivalency within the
immunoconjugates determines the ability to over-
come the FH- and mCRP-mediated CIT. The asso-
ciation of two FHR4 multimers binding to two
distinct HER2 epitopes further enhances FHR4
densities and deregulation efficacy, in particular on
HER2 tumour cell lines that are resistant to com-
plement attack. Under physiological conditions, FH,
by preventing C3-convertase formation, maintains
the density of C3b molecules on host surfaces (Har-
rison and Lachmann, 1980) below a critical thresh-
old from where C3b amplification proceeds without
control (Jozsi et al., 2015). When FHR4 multimers
do efficiently antagonise FH and neutralise the first
level of control of the AP, overexpressed mCRPs
exert an additional level of control that will limit at
different degrees the lytic MAC densities. Combined
FHR4 multimers, however, succeeded in leading to
60% in cell death in the case of the most resistant
tumour cell line used in this study (Fig. 5A). These
results are in line with previous work showing that
the neutralisation of FH with a specific antibody
resulted in increased C3 fragment deposition and
up to threefold CDC of colorectal cancer cells (Wil-
czek et al., 2008).
Besides CDC, we showed that opsonised target
tumour cells were phagocytosed by M2-macrophages
in a complement-dependent manner. Multimeric
FHR4 immunoconjugate-mediated AP activation
should therefore further potentiate the anti-tumour
response via complement receptors on different cell
types (macrophages, NK cells), resulting in enhanced
CDCC or CDCP and the recruitment and/or activa-
tion of effector cells. Figure 9 summarises the mecha-
nism of action of FHR4 immunoconjugates. A
limitation of this approach, like for all cancer
immunotherapies, is the possibility of loss of HER2
overexpression overtime, either for primary tumours
or for metastatic cells. It has been reported, however,
that changes in HER2 expression actually seem to be
extremely rare although a few cases have been report-
ed, and the HER2 expression is stable between metas-
tases and corresponding primary tumours (Carlsson
et al., 2004).
5. Conclusions
In conclusion, we describe in the present work an
innovative strategy of destructive cell targeting consist-













































Fig. 9. Mechanism of action of high FHR4-valence immunoconjugates to activate AP on HER2 tumours cells and CDC. Optimised high
FHR4-valence heteromultimeric immunoconjugates, but not low-FHR4 valence counterparts, activate C3b on target tumour cells by
neutralising FH, allowing overcoming FH-mediated CIT and by directly activating the AP by allowing the formation of the FHR4-bound C3bBb
convertases. Multivalent expression of FHR4 is key to allow local selective efficient competition with FH on tumour cell surfaces.
Depending on mCRP overexpression pattern on target tumours, multimer-mediated convertase formation and subsequent MAC densities
can partially be controlled, but not prevented, leading in our hands from about 100% to 60% direct lysis according to the resistance of the
cell to complement attack. Finally, C3b breakdown products on opsonised tumour targets are recognised by macrophages, allowing tumour
cell clearance by CDCP. FI, factor I; FD, factor D.
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FH-mediated CIT and overactivating AP on target
tumour cells. The few therapeutic mAbs whose activity
lies in part in CDC are used in clinical practice to treat
CLL and non-Hodgkin’s lymphoma (Winiarska et al.,
2011). FHR4 multimeric immunoconjugates targeting
CD20 – by replacing the anti-HER2 targeting system –
may therefore have a higher cytolytic potential in lym-
phoma cells than in solid tumour cells, whereas it has
been shown that abrogation of the FH function in
combination with ofatumumab or rituximab resulted
in an increased susceptibility of primary CLL cells to
CDC (Horl et al., 2013).
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